RxDoctor Payments Data

John Edelen, MD

Cardiovascular Disease · Orinda, CANPI 1831183383

Payments from drug & device makers

$3,270in general payments, 2019–2025

Across 116 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$303
  • E.r. Squibb & Sons, L.L.C.$216
  • Amgen$164
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$148
  • Bardy Diagnostics, Inc.$132
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,24699%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,270 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$361,606
Medicare patients
1,038
Services billed
3,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban433$582,884
EntrestoSacubitril/Valsartan159$229,041
XareltoRivaroxaban95$125,228
FarxigaDapagliflozin Propanediol99$120,660
Repatha SureclickEvolocumab43$47,290
JardianceEmpagliflozin30$31,984
BrilintaTicagrelor22$16,892
Metoprolol Succinate545$9,920
Atorvastatin Calcium640$8,041
Praluent PenAlirocumab12$5,927
Ezetimibe136$4,614
Ranolazine ErRanolazine36$4,561
Bumetanide90$3,872
Diltiazem 24hr Er (Cd)Diltiazem Hcl84$3,113
Losartan Potassium219$3,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$582,884433 claims
NovartisEntresto$303$229,041159 claims
AstraZenecaFarxiga, Brilinta$53$137,551121 claims
Johnson & JohnsonXarelto$20$125,22895 claims
Boehringer IngelheimJardiance$111$31,98430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Orinda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →